FdaApplication
BLA 125590
Identifiers
- fda_app_no: BLA125590
Properties
| Property | Value |
|---|---|
| applicant_name | ADMA Biologics, Inc. |
| application_type | BLA |
| approval_date | 2019-04-01 |
Revenue by product
ASCENIV
| Period | Revenue |
|---|---|
| Q2 2026 | $102.9M |
| Q1 2026 | $97.5M |
| Q2 2025 | $83.3M |
| Q1 2025 | $76.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ASCENIV | — | 5G/50ML | Injection |
1 product